EBAC

NASDAQ

European Biotech Acquisition Corp.

SectorFinanceIndustryBlank ChecksIPO2021

$11.31+0.21 (+1.89%)

News25/Ratings0

European Biotech Acquisition Corp. does not have significant operations. It intends to effect a merger, share exchange, asset acquisition, share purchase, reorganization, or similar business combination with one or more businesses or entities. The company was incorporated in 2021 and is based in Amsterdam, the Netherlands.

Latest news

25 items

1137dSEC
SEC Form 15-12G filed by European Biotech Acquisition Corp.
15-12G - European Biotech Acquisition Corp. (0001841258) (Filer)
1148dSEC
SEC Form 25-NSE/A filed by European Biotech Acquisition Corp. (Amendment)
25-NSE/A - European Biotech Acquisition Corp. (0001841258) (Subject)
1150dSEC
European Biotech Acquisition Corp. filed SEC Form 8-K: Leadership Update, Submission of Matters to a Vote of Security Holders, Other Events, Financial Statements and Exhibits
8-K - European Biotech Acquisition Corp. (0001841258) (Filer)
1151dSEC
SEC Form 10-K filed by European Biotech Acquisition Corp.
10-K - European Biotech Acquisition Corp. (0001841258) (Filer)
1157dSEC
European Biotech Acquisition Corp. filed SEC Form 8-K: Creation of a Direct Financial Obligation, Financial Statements and Exhibits
8-K - European Biotech Acquisition Corp. (0001841258) (Filer)
1164dSEC
SEC Form DEFA14A filed by European Biotech Acquisition Corp.
DEFA14A - European Biotech Acquisition Corp. (0001841258) (Filer)
1164d13D/G
SEC Form SC 13G filed by European Biotech Acquisition Corp.
SC 13G - European Biotech Acquisition Corp. (0001841258) (Subject)
1165dSEC
European Biotech Acquisition Corp. filed SEC Form 8-K: Creation of a Direct Financial Obligation, Financial Statements and Exhibits
8-K - European Biotech Acquisition Corp. (0001841258) (Filer)
1165d13D/G
SEC Form SC 13G filed by European Biotech Acquisition Corp.
SC 13G - European Biotech Acquisition Corp. (0001841258) (Subject)
1172d13D/G
SEC Form SC 13G/A filed by European Biotech Acquisition Corp. (Amendment)
SC 13G/A - European Biotech Acquisition Corp. (0001841258) (Subject)
1175dSEC
SEC Form DEFM14A filed by European Biotech Acquisition Corp.
DEFM14A - European Biotech Acquisition Corp. (0001841258) (Filer)
1179dSEC
SEC Form 425 filed by European Biotech Acquisition Corp.
425 - European Biotech Acquisition Corp. (0001841258) (Subject)
1179dSEC
European Biotech Acquisition Corp. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Financial Statements and Exhibits
8-K - European Biotech Acquisition Corp. (0001841258) (Filer)
1226dSEC
SEC Form 425 filed by European Biotech Acquisition Corp.
425 - European Biotech Acquisition Corp. (0001841258) (Subject)
1226dSEC
European Biotech Acquisition Corp. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits
8-K - European Biotech Acquisition Corp. (0001841258) (Filer)
1256dSEC
SEC Form 10-Q filed by European Biotech Acquisition Corp.
10-Q - European Biotech Acquisition Corp. (0001841258) (Filer)
1284dSEC
European Biotech Acquisition Corp. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Regulation FD Disclosure, Financial Statements and Exhibits
8-K - European Biotech Acquisition Corp. (0001841258) (Filer)
1284dNEWS
Oculis SA And European Biotech Acquisition Corp Announce Business Combination Agreement To Create Nasdaq-lListed BioPharmaceutical Company Driving Breakthrough Innovations In Ophthalmology
Oculis SA and European Biotech Acquisition Corp announce business combination agreement to create Nasdaq-listed biopharmaceutical company driving breakthrough innovations in ophthalmology Oculis is focused on becoming a leading global ophthalmic biopharmaceutical company with product candidates to address areas of significant medical needs, including diabetic macular edema (DME), dry eye disease (DED), and neuro-retina indications such as glaucoma, affecting growing patient populations Net proceeds expected to support advanced clinical pipeline of multiple innovative product candidates with near term potential value catalysts, potentially including the first topical eye-drop for DME, the
1284dPR
Oculis SA and European Biotech Acquisition Corp announce business combination agreement to create Nasdaq-listed biopharmaceutical company driving breakthrough innovations in ophthalmology
Oculis SA and European Biotech Acquisition Corp announce business combination agreement to create Nasdaq-listed biopharmaceutical company driving breakthrough innovations in ophthalmology Oculis is focused on becoming a leading global ophthalmic biopharmaceutical company with product candidates to address areas of significant medical needs, including diabetic macular edema (DME), dry eye disease (DED), and neuro-retina indications such as glaucoma, affecting growing patient populationsNet proceeds expected to support advanced clinical pipeline of multiple innovative product candidates with near term potential value catalysts, potentially including the first topical eye-drop for DME, the fir
1347dSEC
SEC Form 10-Q filed by European Biotech Acquisition Corp.
10-Q - European Biotech Acquisition Corp. (0001841258) (Filer)
1438dSEC
SEC Form 10-Q filed by European Biotech Acquisition Corp.
10-Q - European Biotech Acquisition Corp. (0001841258) (Filer)
1484dSEC
SEC Form 10-K filed by European Biotech Acquisition Corp.
10-K - European Biotech Acquisition Corp. (0001841258) (Filer)
1529d13D/G
SEC Form SC 13G/A filed by European Biotech Acquisition Corp. (Amendment)
SC 13G/A - European Biotech Acquisition Corp. (0001841258) (Subject)
1535d13D/G
SEC Form SC 13G filed by European Biotech Acquisition Corp.
SC 13G - European Biotech Acquisition Corp. (0001841258) (Subject)
1547d13D/G
SEC Form SC 13G/A filed by European Biotech Acquisition Corp. (Amendment)
SC 13G/A - European Biotech Acquisition Corp. (0001841258) (Subject)